Arbutus Biopharma (ABUS) Stock Forecast, Price & News

Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

Is Arbutus Biopharma a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arbutus Biopharma stock.
View analyst ratings for Arbutus Biopharma or view top-rated stocks.

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Arbutus Biopharma.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) released its quarterly earnings data on Thursday, May, 5th. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.02. The biopharmaceutical company had revenue of $12.58 million for the quarter, compared to analyst estimates of $5.77 million. Arbutus Biopharma had a negative net margin of 352.49% and a negative trailing twelve-month return on equity of 121.30%. During the same quarter last year, the firm posted ($0.21) EPS.
View Arbutus Biopharma's earnings history.

What price target have analysts set for ABUS?

4 brokerages have issued twelve-month price objectives for Arbutus Biopharma's shares. Their forecasts range from $5.00 to $9.00. On average, they expect Arbutus Biopharma's share price to reach $7.13 in the next year. This suggests a possible upside of 222.4% from the stock's current price.
View analysts' price targets for Arbutus Biopharma or view top-rated stocks among Wall Street analysts.

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the following people:

• Mr. William H. Collier, Pres, CEO & Director (Age 61, Pay $1.03M)
• Mr. David C. Hastings CPA, CFO & Chief Accounting Officer (Age 61, Pay $647.1k)
• Dr. Michael J. Sofia Ph.D., Chief Scientific Officer (Age 64, Pay $670.22k)
• Pam Murphy, Investor Relations Consultant
• Ms. Lisa M. Caperelli, VP of Investor Relations
• Dr. Elizabeth Howard, Exec. VP, Gen. Counsel, Chief Compliance Officer & Sec. (Age 68)
• Dr. Gaston Picchio Ph.D., Chief Devel. Officer (Age 58)
• Mr. Michael J. McElhaugh, Chief Bus. Officer (Age 47)
• Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C, Q.C., Sec. (Age 71)

What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?

6 employees have rated Arbutus Biopharma CEO Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among Arbutus Biopharma's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Arbutus Biopharma's key competitors?

Some companies that are related to Arbutus Biopharma include BELLUS Health (BLUSF), 23andMe (ME), Prothena (PRTA), IVERIC bio (ISEE), Mawson Infrastructure Group (WIZP), Madrigal Pharmaceuticals (MDGL), Prometheus Biosciences (RXDX), Cryoport (CYRX), Agios Pharmaceuticals (AGIO), Celularity (CELU), NGM Biopharmaceuticals (NGM), Vectura Group (VEGPF), Innoviva (INVA), Cassava Sciences (SAVA) and MannKind (MNKD).
View all of ABUS's competitors.

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.59%), Vanguard Group Inc. (3.19%), Two Seas Capital LP (1.48%), Assenagon Asset Management S.A. (1.43%), State Street Corp (1.19%) and Goldman Sachs Group Inc. (1.04%).
View institutional ownership trends for Arbutus Biopharma.

Which major investors are selling Arbutus Biopharma stock?

ABUS stock was sold by a variety of institutional investors in the last quarter, including Group One Trading L.P., Jacob Asset Management of New York LLC, PEAK6 Investments LLC, Jane Street Group LLC, HAP Trading LLC, Simplex Trading LLC, Cutler Group LP, and XTX Topco Ltd.
View insider buying and selling activity for Arbutus Biopharma or view top insider-selling stocks.

Which major investors are buying Arbutus Biopharma stock?

ABUS stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Two Seas Capital LP, Goldman Sachs Group Inc., BlackRock Inc., Wellington Management Group LLP, Vanguard Group Inc., State Street Corp, and Bank of Montreal Can.
View insider buying and selling activity for Arbutus Biopharma or or view top insider-buying stocks.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $2.21.

How much money does Arbutus Biopharma make?

Arbutus Biopharma has a market capitalization of $328.69 million and generates $10.99 million in revenue each year. The biopharmaceutical company earns $-76.25 million in net income (profit) each year or ($0.730010) on an earnings per share basis.

How many employees does Arbutus Biopharma have?

Arbutus Biopharma employs 85 workers across the globe.

When was Arbutus Biopharma founded?

Arbutus Biopharma was founded in 1992.

What is Arbutus Biopharma's official website?

The official website for Arbutus Biopharma is www.arbutusbio.com.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The biopharmaceutical company can be reached via phone at (267) 469-0914, via email at [email protected], or via fax at 604-419-3201.